BCM
XERS icon

Bayesian Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Bayesian Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-70,800
Closed -$576K – 557
2025
Q3 		$576K Buy
+70,800
New +$470K 0.12% 254
2025
Q2 		– Sell
-59,300
Closed -$326K – 909
2025
Q1 		$326K Buy
+59,300
New +$239K 0.05% 372
2024
Q2 		– Sell
-16,732
Closed -$37K – 1145
2024
Q1 		$37K Buy
+16,732
New +$43.3K ﹤0.01% 738

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bayesian Capital Management's XERS Position: Q4 2025 in Review

Bayesian Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 70,800 shares — an estimated $576K sold.

Bayesian Capital Management first reported a position in XERS in Q1 2024 and held it in 3 quarters. The position peaked at $576K in Q3 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Bayesian Capital Management reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 70,800 Xeris Biopharma Holdings shares in Q4 2025, an estimated $576K.
  • Bayesian Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2024 and held it in 3 quarters.
  • Bayesian Capital Management's Xeris Biopharma Holdings position peaked at $576K in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.